Roxair 500 mcg (Tablet)

Unit Price: ৳ 15.00 (3 x 10: ৳ 450.00)

Strip Price: ৳ 150.00

Medicine Details

Category	Details
Generic	Roflumilast tablet
Company	Incepta pharmaceuticals ltd

Phosphodiesterase-4 (PDE-4) inhibitor
Potential antiinflammatory and antimodulatory effects in the pulmonary system
Increased levels of intracellular cyclic AMP responsible for therapeutic actions

Recommended dose: one tablet of 500 micrograms Roflumilast once daily
May need to be taken for several weeks to achieve its effect
Studied in clinical trials for up to one year
No dose adjustment for elderly (65 years and older)
No dose adjustment for renal impairment
Caution in patients with mild hepatic impairment (Child-Pugh A)
Patients with moderate or severe hepatic impairment (Child-Pugh B or C) must not take

No proven cases of hazardous interactions
Case report of interaction with ethanol and a compound containing pyrimethamine with dapsone
Potentiation of betahistine with salbutamol
Concurrent administration of H1 antagonists may cause mutual attenuation of effect

Adverse reactions experienced by approximately 16% of patients in clinical COPD studies
Common adverse reactions: diarrhoea, weight decreased, nausea, abdominal pain, headache
Mostly mild or moderate reactions
Adverse reactions mainly occurred within the first weeks of therapy and mostly resolved on continued treatment
Various adverse reactions under respective MedDRA frequency classification

Limited data from use in pregnant women
Reproductive toxicity shown in animal studies
Not recommended during pregnancy and in women of childbearing potential not using contraception
Demonstrated to cross the placenta in pregnant rats
Excretion of Roflumilast or its metabolites in milk
Risk to the suckling child cannot be excluded
Not recommended during breastfeeding

Inform patients about risks and precautions for safe use
Not indicated as rescue medicinal product for the relief of acute bronchospasms
Weight decrease may occur and should be monitored
Roxair should not be initiated or continued in certain severe clinical conditions
Associated with an increased risk of psychiatric disorders
Treatment reassessment in case of persistent intolerability
Concomitant treatment with theophylline not recommended
Roxair tablets contain lactose, not suitable for patients with rare hereditary problems

Observed symptoms after single oral doses of 2,500 micrograms and one single dose of 5,000 micrograms
In case of overdose, appropriate supportive medical care is recommended
Haemodialysis not likely to be efficient method of removal